AMO Pharma Limited a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced completion

Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, establishes LumaCina business unit under Bridgewest

Ascentage Pharma a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis Band age-related diseases, today announced that it recently

TraceLink Inc., the leading digital network platform company connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced Multienterprise Information

Navamedic ASA a Nordic pharma company and provider of high-quality products to hospitals and pharmacies, has today amended its cash offer to acquire all shares in Sensidose AB

Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced completion of the safety evaluation stage of the highest dose cohort of patients with acute myeloid leukemia (AML) who relapsed after or were refractory

Zucara Therapeutics Inc., a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for ZT-01 for the prevention

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company's high potency vial line to manufacture a commercial product.

Nordic Capital has agreed to acquire a majority share in corpuls to support the Company's next phase of growth, in partnership with the founding family. corpuls is an innovative medical